177,500 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Bought by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund bought a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 177,500 shares of the company's stock, valued at approximately $7,533,000. Healthcare of Ontario Pension Plan Trust Fund owned 0.65% of GeneDx as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Acadian Asset Management LLC acquired a new position in GeneDx during the 2nd quarter worth $34,000. nVerses Capital LLC acquired a new stake in shares of GeneDx in the 2nd quarter valued at about $50,000. CWM LLC acquired a new stake in GeneDx in the 3rd quarter valued at approximately $89,000. American Century Companies Inc. lifted its position in shares of GeneDx by 36.1% in the second quarter. American Century Companies Inc. now owns 17,258 shares of the company's stock worth $451,000 after purchasing an additional 4,573 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of GeneDx in the 3rd quarter valued at about $198,000. Institutional investors and hedge funds own 61.72% of the company's stock.

GeneDx Stock Down 1.3 %

Shares of WGS traded down $1.04 on Friday, reaching $78.39. The company's stock had a trading volume of 185,920 shares, compared to its average volume of 451,858. The stock has a market capitalization of $2.15 billion, a PE ratio of -25.21 and a beta of 2.11. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a twelve month low of $1.45 and a twelve month high of $89.11. The firm has a fifty day moving average of $63.68 and a 200-day moving average of $41.60.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.25. The firm had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business's revenue for the quarter was up 44.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.82) EPS. Equities analysts predict that GeneDx Holdings Corp. will post -0.24 EPS for the current year.

Insider Buying and Selling at GeneDx

In other news, Director Jason Ryan sold 31,510 shares of GeneDx stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $71.28, for a total value of $2,246,032.80. Following the completion of the transaction, the director now owns 15,490 shares of the company's stock, valued at $1,104,127.20. The trade was a 67.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder School Of Medicine At Mo Icahn sold 865,800 shares of the company's stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $75.00, for a total transaction of $64,935,000.00. Following the transaction, the insider now owns 2,866,833 shares in the company, valued at $215,012,475. This represents a 23.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,109,109 shares of company stock valued at $81,980,692 in the last quarter. 27.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on WGS shares. Craig Hallum upped their target price on shares of GeneDx from $70.00 to $95.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Wells Fargo & Company lifted their price objective on shares of GeneDx from $34.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group increased their target price on GeneDx from $54.00 to $70.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $59.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.